Mirae Asset Global ETFs Holdings’s Iovance Biotherapeutics IOVA Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$959K	Buy	230,057 +41,143	+22%	+$156K	﹤0.01%	1655
2026 Q1	$657K	Buy	188,914 +4,946	+3%	+$15.8K	﹤0.01%	1737
2025 Q4	$504K	Buy	183,968 +39,052	+27%	+$90.3K	﹤0.01%	1893
2025 Q3	$316K	Sell	144,916 -9,781	-6%	-$23.1K	﹤0.01%	2084
2025 Q2	$266K	Sell	154,697 -28,094	-15%	-$69.9K	﹤0.01%	2139
2025 Q1	$613K	Buy	182,791 +4,488	+3%	+$23.1K	﹤0.01%	1756
2024 Q4	$1.31M	Buy	178,303 +13,987	+9%	+$130K	﹤0.01%	1404
2024 Q3	$1.55M	Buy	164,316 +18,556	+13%	+$176K	﹤0.01%	1290
2024 Q2	$1.17M	Buy	+145,760	New	+$1.56M	﹤0.01%	1371

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's IOVA Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Iovance Biotherapeutics (IOVA) stake by 22% in Q2 2026, buying an estimated $156K and bringing the position to 230,057 shares worth $959K. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Mirae Asset Global ETFs Holdings first reported a position in IOVA in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.55M in Q3 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Mirae Asset Global ETFs Holdings held 230,057 shares of Iovance Biotherapeutics worth $959K as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 41,143 Iovance Biotherapeutics shares in Q2 2026, an estimated $156K.
Iovance Biotherapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1655 holding.
Mirae Asset Global ETFs Holdings first reported a position in Iovance Biotherapeutics in Q2 2024 and has held it in 9 quarters since.
Mirae Asset Global ETFs Holdings's Iovance Biotherapeutics position peaked at $1.55M in Q3 2024.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.